Methods of expressing LIM mineralization protein in non-osseous cells
    8.
    发明申请
    Methods of expressing LIM mineralization protein in non-osseous cells 有权
    在非骨细胞中表达LIM矿化蛋白的方法

    公开(公告)号:US20100239545A9

    公开(公告)日:2010-09-23

    申请号:US10292951

    申请日:2002-11-13

    Abstract: Methods of expressing LIM mineralization protein in non-osseous mammalian cells, such as stem cells or intervertebral disc cells (e.g., cells of the annulus fibrosus, or cells of the nucleus pulposus) are described. The methods involve transfecting the cells with an isolated nucleic acid comprising a nucleotide sequence encoding a LIM mineralization protein operably linked to a promoter. Transfection may be accomplished ex vivo or in vivo by direct injection of virus or naked DNA, or by a nonviral vector such as a plasmid. Expression of the LIM mineralization protein can stimulate proteoglycan and/or collagen production in cells capable of producing proteoglycyan and/or collagen. Methods for treating disc disease associated with trauma or disc degeneration are also described.

    Abstract translation: 描述了在非骨骼哺乳动物细胞中表达LIM矿化蛋白的方法,例如干细胞或椎间盘细胞(例如,纤维环的细胞或髓核的细胞)。 所述方法涉及用分离的核酸转染细胞,所述分离的核酸包含可操作地连接到启动子的编码LIM矿化蛋白的核苷酸序列。 转染可以通过直接注射病毒或裸露DNA或非病毒载体如质粒在体内或体内完成。 LIM矿化蛋白的表达可以刺激能够产生蛋白多糖和/或胶原的细胞中的蛋白聚糖和/或胶原产生。 还描述了与创伤或椎间盘退变相关的椎间盘疾病的治疗方法。

    Mechanisms of osteoinduction by LIM mineralization protein-1 (LMP-1)
    9.
    发明申请
    Mechanisms of osteoinduction by LIM mineralization protein-1 (LMP-1) 有权
    LIM矿化蛋白-1(LMP-1)诱导骨诱导机制

    公开(公告)号:US20070027081A1

    公开(公告)日:2007-02-01

    申请号:US11385612

    申请日:2006-03-21

    CPC classification number: A61K38/1709 A61K38/1875 A61K2300/00

    Abstract: The present invention relates to the methods and compositions for the treatment of subjects having compromised bone conditions. Specifically, the invention relates to combinatorial therapeutic strategies including small molecules and peptide mimics of LIM mineralization proteins, particularly LMP-1, to overcome the dose-related translational barriers for BMP-2 therapeutics.

    Abstract translation: 本发明涉及用于治疗受损骨患者的方法和组合物。 具体地,本发明涉及包括LIM矿化蛋白(特别是LMP-1)的小分子和肽模拟物的组合治疗策略,以克服BMP-2治疗剂的剂量相关翻译屏障。

Patent Agency Ranking